The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Safety and pharmacokinetics of mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Matsubara N, Ayanambakkam A, Carles J, Zhang T , Mellado B, Moreno V, Velasco G, Dunshee C, Schweizer M, Qiang W, Garmezy B, Mittapalli R, Tougias J, Andreu-Vieyra C, Soman N, Gordoa TA
Mevrometostat (PF-06821497) | June 2, 2025 | ASCO 2025
C2321001 | NCT03460977
Presentation
Mevrometostat (PF-06821497), an EZH2 inhibitor, in combination with enzalutamide in patients with mCRPC: A randomized dose-expansion study
Schweizer M, Calvo M, Moreno V, Mellado B, Castellanos D, Spira A, Wei Q, Carles J, Garmezy B, Kwak C, Ługowska I, Penkov K, Shore N, Liu L, Mittapalli R, Tougias J, Andreu-Vieyra C, Soman N, Gordoa TA
Mevrometostat (PF-06821497) | February 13, 2025 | ASCO GU 2025
C2321001 | NCT03460977
Poster
Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration‑resistant prostate cancer previously treated with abiraterone: The phase 3, randomized MEVPRO‑1 study
Agarwal N, Schweizer M, Castro E, Azad A, George DJ, Chakrabarti J, Narayanan S, Tang Y, Fizazi K
Mevrometostat (PF-06821497) | December 4, 2024 | SUO 2024
C2321014 | NCT06551324
Poster
Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)
Schweizer MT, Penkov K, Choudhury A, EC Aller, Frank R, Liu L, Mittapalli R, Tougias J, Andreu-Vieyra C, Bowler T, Soman N, Johnson M
Mevrometostat (PF-06821497) | May 31, 2024 | ASCO 2024
C2321001 | NCT03460977